262 related articles for article (PubMed ID: 35503373)
1. Vaccines and myasthenia gravis: a comprehensive review and retrospective study of SARS-CoV-2 vaccination in a large cohort of myasthenic patients.
Sansone G; Bonifati DM
J Neurol; 2022 Aug; 269(8):3965-3981. PubMed ID: 35503373
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 vaccination and new-onset myasthenia gravis: A report of 7 cases and review of the literature.
Ramdas S; Hum RM; Price A; Paul A; Bland J; Burke G; Farrugia M; Palace J; Storrie A; Ho P; Standing E; Lilleker JB; Jungbluth H
Neuromuscul Disord; 2022 Oct; 32(10):785-789. PubMed ID: 36130855
[TBL] [Abstract][Full Text] [Related]
3. Safety and tolerability of SARS-Cov-2 vaccination in patients with myasthenia gravis: A multicenter experience.
Farina A; Falso S; Cornacchini S; Spagni G; Monte G; Mariottini A; Massacesi L; Barilaro A; Evoli A; Damato V
Eur J Neurol; 2022 Aug; 29(8):2505-2510. PubMed ID: 35390184
[TBL] [Abstract][Full Text] [Related]
4. New-onset myasthenia gravis after mRNA SARS-CoV-2 vaccination: a case series.
Fanella G; Baiata C; Candeloro E; Toscano G; Colnaghi S; Mauri M; Cariddi LP; Rebecchi V; Solazzo F; Banfi P; Piatti M; Ferrarese C; Versino M
Neurol Sci; 2022 Oct; 43(10):5799-5802. PubMed ID: 35870026
[TBL] [Abstract][Full Text] [Related]
5. BNT162b2 mRNA COVID-19 vaccine three-dose safety and risk of COVID-19 in patients with myasthenia gravis during the alpha, delta, and omicron waves.
Doron A; Piura Y; Vigiser I; Kolb H; Regev K; Nesher N; Karni A
J Neurol; 2022 Dec; 269(12):6193-6201. PubMed ID: 35907046
[TBL] [Abstract][Full Text] [Related]
6. Safety of inactivated SARS-CoV-2 vaccines in myasthenia gravis: A survey-based study.
Li HY; Shao LY; Song M; Hu SM; Yue YX; Li HF
Front Immunol; 2022; 13():923017. PubMed ID: 35990671
[TBL] [Abstract][Full Text] [Related]
7. Safety of mRNA COVID-19 vaccines in patients with well-controlled myasthenia gravis.
Gamez J; Gamez A; Carmona F
Muscle Nerve; 2022 Nov; 66(5):612-617. PubMed ID: 36029224
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
9. The safety of COVID-19 vaccines in patients with myasthenia gravis: A scoping review.
Peng S; Tian Y; Meng L; Fang R; Chang W; Yang Y; Li S; Shen Q; Ni J; Zhu W
Front Immunol; 2022; 13():1103020. PubMed ID: 36618419
[TBL] [Abstract][Full Text] [Related]
10. The impact of SARS-CoV-2 immunization on COVID-19 disease course in people with myasthenia gravis.
Bakirtzis C; Boziki MK; Karakasi MV; Moysiadis T; Grigoriadis N
Muscle Nerve; 2023 May; 67(5):412-416. PubMed ID: 36814101
[TBL] [Abstract][Full Text] [Related]
11. COVID-19 Vaccination and Late-Onset Myasthenia Gravis: A New Case Report and Review of the Literature.
Virgilio E; Tondo G; Montabone C; Comi C
Int J Environ Res Public Health; 2022 Dec; 20(1):. PubMed ID: 36612789
[TBL] [Abstract][Full Text] [Related]
12. To Be or Not To Be Vaccinated: That Is a Question in Myasthenia Gravis.
Zhou Q; Zhou R; Yang H; Yang H
Front Immunol; 2021; 12():733418. PubMed ID: 34603311
[TBL] [Abstract][Full Text] [Related]
13. Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study.
Wong CKH; Lau KTK; Xiong X; Au ICH; Lai FTT; Wan EYF; Chui CSL; Li X; Chan EWY; Gao L; Cheng FWT; Tang SCW; Wong ICK
PLoS Med; 2022 Jun; 19(6):e1004018. PubMed ID: 35727759
[TBL] [Abstract][Full Text] [Related]
14. Immune Response and Safety of SARS-CoV-2 mRNA-1273 Vaccine in Patients With Myasthenia Gravis.
Reyes-Leiva D; López-Contreras J; Moga E; Pla-Juncà F; Lynton-Pons E; Rojas-Garcia R; Turon-Sans J; Querol L; Olive M; Álvarez-Velasco R; Caballero-Ávila M; Carbayo Á; Vesperinas-Castro A; Domingo P; Illa I; Gallardo E; Cortés-Vicente E
Neurol Neuroimmunol Neuroinflamm; 2022 Jul; 9(4):. PubMed ID: 35728947
[TBL] [Abstract][Full Text] [Related]
15. Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis.
Ciampi E; Uribe-San-Martin R; Soler B; García L; Guzman J; Pelayo C; Jürgensen L; Guzman I; Vera F; Galleguillos L; Cárcamo C
Mult Scler Relat Disord; 2022 Mar; 59():103690. PubMed ID: 35182880
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 Vaccination and Neuroimmunological Disease: A Review.
Willison AG; Pawlitzki M; Lunn MP; Willison HJ; Hartung HP; Meuth SG
JAMA Neurol; 2024 Feb; 81(2):179-186. PubMed ID: 38227318
[TBL] [Abstract][Full Text] [Related]
17. A Case of COVID-19 Vaccine Associated New Diagnosis Myasthenia Gravis.
Chavez A; Pougnier C
J Prim Care Community Health; 2021; 12():21501327211051933. PubMed ID: 34709075
[TBL] [Abstract][Full Text] [Related]
18. Effects of anti-SARS-CoV-2 vaccination on safety and disease exacerbation in patients with Behçet syndrome in a monocentric cohort.
Apaydin H; Erden A; Güven SC; Armağan B; Konak HE; Polat B; Afşin Y; Kaygisiz M; Omma A; Kucuksahin O
Int J Rheum Dis; 2022 Sep; 25(9):1068-1077. PubMed ID: 35851753
[TBL] [Abstract][Full Text] [Related]
19. An observational study on the safety of COVID-19 vaccination in patients with myasthenia gravis.
Wang HY; Qiu L; Ou CY; Lin ZQ; Huang ZD; Chen P; Ma Q; Lu YR; Ran H; Liu WB
Neurol Sci; 2023 Jul; 44(7):2239-2245. PubMed ID: 37160544
[TBL] [Abstract][Full Text] [Related]
20. Safety and Immunogenicity of Additional SARS-CoV-2 Vaccinations in a Patient With Myasthenia Gravis on Mycophenolate: A Case Report.
McNeish BL; Colletti RB; Hehir MK
J Clin Neuromuscul Dis; 2022 Dec; 24(2):113-114. PubMed ID: 36409346
[No Abstract] [Full Text] [Related]
[Next] [New Search]
